Success Stories: Chinese Senior Research Scientist Secures NIW and EB1B Approvals for Tissue Engineering and Bioadhesive Device Research

Client’s Testimonial:

“Thank you so much for this wonderful news! I would like to thank my attorney and the WeGreened team for your professionalism and dedication to the case preparation. It has been a smooth and pleasant experience working with you!”

On November 3^rd, 2023, and January 29^th, 2025, we received another EB-2 NIW (National Interest Waiver) and EB1B (Outstanding Researcher/Professor) approvals for a Senior Research Scientist in the field of Mechanical Engineering (Approval Notice).

General Field: Mechanical Engineering

Position at the Time of Case Filing: Senior Research Scientist

Country of Origin: China

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: November 3^rd, 2023 (NIW); January 29^th, 2025 (EB1B)

Processing Time: 11 days (NIW); 12 days (EB1B, Premium Processing Requested)

Case Summary:

We are pleased to share the successful NIW and EB1B approvals of a senior research scientist from China. At the time of filing, he was conducting research in the United States focused on tissue engineering and bioadhesive materials. His work applies advanced mechanical engineering principles to develop hydrogels, scaffolds, and adhesive devices that address critical challenges in regenerative medicine, wound healing, and surgical care. By demonstrating both national importance and extraordinary ability, he was able to secure approvals in two distinct immigration categories.

Research with Substantial Merit and National Importance

The client’s research develops advanced biomaterials and bioadhesive medical devices that improve recovery from trauma, manage bleeding, and support regenerative therapies. This work holds clear national importance, as it strengthens healthcare innovation, reduces treatment costs, and supports U.S. priorities in biomedical technology and public health.

Scholarly Contributions and Recognition

The client has authored 18 peer-reviewed journal articles, 2 conference papers, and a book chapter, with studies published in leading journals such as Advanced Materials and Nature Communications. His work has been cited over 1,000 times, with multiple papers ranked among the top 1–10% most cited in materials science.

He has also completed at least 60 peer reviews for high-impact journals, underscoring his standing as a trusted authority in mechanical engineering and biomedical materials.

Expert Recognition

Independent recommenders provided strong endorsements, emphasizing the originality and utility of his research.

One expert remarked:

“In his research, [client] facilitates innovation in the field of mechanical engineering by providing new medical devices that are not limited by the challenges faced by traditional devices and technologies.”

This testimony reinforced the petition’s core argument: that his work is not only innovative in theory but also practical in application, making it highly valuable to healthcare providers and patients in the United States.

Dual Approvals and Outlook

The I-140 NIW petition was filed on October 23, 2023, and approved on November 3, 2023. His EB1B petition, filed on January 17, 2025, was approved on January 29, 2025. Both were filed with premium processing.

With NAILG’s guidance, the client secured approval under both NIW and EB1B. He is now well-positioned to continue advancing bioadhesive devices and tissue engineering research in the United States, supporting innovation in regenerative medicine and reinforcing U.S. leadership in healthcare technology.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.